A Phase I, Double-blind, Randomized, Placebo-controlled, Dose Escalating Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002 in the Treatment of Chronic Hepatitis B (CHB) Infection in Adults ≥ 18 Years Old
Overview
- Phase
- Phase 1
- Intervention
- YS-HBV-002
- Conditions
- Not specified
- Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
- Enrollment
- 16
- Locations
- 1
- Primary Endpoint
- Incidence of AEs within 30 minutes after vaccination.
- Status
- Terminated
- Last Updated
- last year
Overview
Brief Summary
This is the first-in-human Phase I, double-blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, immunogenicity and preliminary efficacy of the YSHBV-002 in the treatment of CHB in adults ≥18 years old. There will be 3 escalating doses of YS-HBV-002 to be administered intramuscularly: 0.5mL, 1.0mL, and 2.0mL.
Detailed Description
This is the first-in-human Phase I, double-blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, immunogenicity and preliminary efficacy of the YSHBV-002 in the treatment of CHB in adults ≥18 years old. There will be 3 escalating doses of YS-HBV-002 to be administered intramuscularly: 0.5mL, 1.0mL, and 2.0mL. Enrollment in the study will sequentially start from the low dose 0.5mL as Group A, then to the mid-dose 1.0mL as Group B and lastly to the high dose of 2.0mL as Group C. Each group will have 16 patients enrolled. The first 4 enrollees in Group A will be sentinel patients and will be allocated at a 1:1 ratio to receive 0.5mL of either YS-HBV-002 or placebo (Table 3). As there is no comparable equivalent to YS-HBV-002 available in the market, the placebo of normal saline solution to be injected intramuscularly will serve as the control in this trial. The next 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to receive 0.5mL of either YS-HBV-002 or placebo. The vaccination regimen will be 1 IM injection every 3 days in the deltoid muscle, alternately for approximately 6 weeks. A total of 14 injections will be administered to each patient.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age ≥ 18 years during screening
- •Body Mass Index (BMI) of 18.5-30 kg/m2
- •Diagnosed or laboratory confirmed to have CHB
- •Have CHB infection for at least 6 months
- •HBsAg titer ≥ 1000 IU/mL
- •HBV DNA ≥ 2000 IU/mL
- •Serum alanine amino transferase (ALT) and aspartate aminotransferase (AST) ≤ 2 × upper limit of normal (ULN)
- •Able to provide informed consent
- •Able and willing to comply with all study procedures throughout the study period of approximately 3 months
- •For female subjects with childbearing potential: must agree to avoid pregnancy throughout the study period of approximately 3 months. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods on avoiding pregnancy include: a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), or the combination of a condom or diaphragm with a spermicide.
Exclusion Criteria
- •Pregnant or breastfeeding or intending to become pregnant within the projected duration of the trial
- •Transient elastography at screening revealing a FibroScan value of ≥ 9 kPa or a previous liver biopsy evidencing hepatic fibrosis at or within 24 months prior to vaccination
- •Patients with hepatitis caused by other etiologies
- •History of or manifestations of liver decompensation (e.g., Child-Pugh Class B or C, or ascites, gastrointestinal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, etc....)
- •Currently participating in or has participated in a study with an IP within 30 days preceding Day 0
- •Fever (axillary temperature ≥ 37.8 ℃)
- •Subjects with abnormal indicators of blood biochemistry and other routine blood tests deemed clinically significant by the investigator
- •History of severe allergic reactions (such as acute anaphylaxis, urticaria, skin eczema, dyspnea, angioneurotic edema, or allergic abdominal pain) or allergy to any of the components of YS-HBV-002
- •Any history of anaphylaxis or angioedema after any vaccination
- •Allergy to kanamycin and aminoglycosides
Arms & Interventions
High dose 2.0mL
Group C ：The first 4 enrollees in Group C will be sentinel patients and will be allocated at a 1:1 ratio to receive 2.0mL of either YS-HBV-002 or placebo(saline solution), The next 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to receive 2.0mL of either YS-HBV-002 or placebo.
Intervention: YS-HBV-002
Low dose 0.5mL
Group A ：The first 4 enrollees in Group A will be sentinel patients and will be allocated at a 1:1 ratio to receive 0.5mL of either YS-HBV-002 or placebo(saline solution), The next 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to receive 0.5mL of either YS-HBV-002 or placebo.
Intervention: YS-HBV-002
Mid-dose 1.0mL
Group B ：The first 4 enrollees in Group B will be sentinel patients and will be allocated at a 1:1 ratio to receive 1.0mL of either YS-HBV-002 or placebo(saline solution), The next 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to receive 1.0mL of either YS-HBV-002 or placebo.
Intervention: YS-HBV-002
Outcomes
Primary Outcomes
Incidence of AEs within 30 minutes after vaccination.
Time Frame: 30 minutes post each vaccination
To assess the safety and tolerability
Incidence of solicited local reactions within 7 days after each vaccination.
Time Frame: 7 days post each vaccination
To assess the safety and tolerability
Incidence of solicited systemic reactions from first vaccination to 7 days after the last vaccination (D1 to D46).
Time Frame: From Day1 to Day46
To assess the safety and tolerability
Incidence of unsolicited AEs, serious adverse events (SAEs) including suspected unexpected serious adverse reactions (SUSARs), adverse events of special interest (AESIs), and AEs leading to withdrawals throughout the study period
Time Frame: From Day1 to Day 90
To assess the safety and tolerability
Secondary Outcomes
- Seroconversion rates of antibodies against HBsAg, HBcAg, and HBeAg.(Day0， Day16， Day34， Day60， Day90)
- Proportion of patients with loss (defined as lower limit of quantitation [LLOQ]) or decline in HBsAg, HBcAg, and HBeAg from baseline to the end of the study and at each specified timepoint.(Day0， Day16， Day34， Day60， Day90)
- Change in serum levels of HBeAg, HBcAg, and HBsAg from baseline to end of study and at each specified timepoint.(Day0， Day16， Day34， Day60， Day90)
- Change in serum levels of HBeAg, HBcAg, and HBsAg from baseline to end of study at each specified timepoint.(Day0， Day16， Day34， Day60， Day90)
- Proportion of patients showing reduction in HBV DNA using PCR for each dose from baseline to the end of the study and at specified timepoints.(Day0， Day16， Day34， Day60， Day90)
- Change in mean log10 of HBV DNA from baseline to end of study and at each specified timepoint.(Day0， Day16， Day34， Day60， Day90)
- GMTs of antibodies against HBsAg, HBcAg and HBeAg at baseline and at pre-defined post-vaccination timepoints.(Day0， Day16， Day34， Day60， Day90)